Synced daily from ClinicalTrials.gov via AACT. Last sync: .
28 Enlicitide Decanoate clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Healthy & Hypercholesterolemia) and 22,873 total planned enrollment. 6 Phase 3 Enlicitide Decanoate trials are listed. 3 Enlicitide Decanoate clinical trials are actively recruiting at 19 U.S. sites across 14 states. Most recent activity: NCT07058077 (Jan 2037).
Where to Participate: All Enlicitide Decanoate Trial Sites in the U.S. (19 sites across 14 states)
Every actively recruiting Enlicitide Decanoatetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
MK-0616-029A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
How many Enlicitide Decanoate clinical trials are there?
28 Enlicitide Decanoate clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 23 are marked completed.
Are Enlicitide Decanoate clinical trials recruiting in 2026?
Yes — 3 Enlicitide Decanoate trials are actively recruiting in 2026, with 19 U.S. sites across 14 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Enlicitide Decanoate being studied for?
Enlicitide Decanoate is being studied for Healthy, Hypercholesterolemia, Familial Hypercholesterolemia, Hypercholesterolaemia, Hyperlipidemia and 6 more. The trials are grouped by indication on this page.
What phase is Enlicitide Decanoate in?
Enlicitide Decanoate clinical trials span 6 Phase 3, 21 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Enlicitide Decanoate clinical trials?
The lead sponsor across the most Enlicitide Decanoate trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Enlicitide Decanoateas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.